Sentences with phrase «gene targeting technology»

However, scientists are still barely scratching the surface of the full capabilities of gene targeting technology.

Not exact matches

The technology's possibilities are staggering — in theory, allowing medical scientists to do everything from cure genetic disorders like sickle cell disease to identify gene targets for combating HIV.

Well, one startup is seeking to take a very different approach: Exonics Therapeutics, which has secured $ 5 million in seed funding from CureDuchenne Ventures to see if the revolutionary new CRISPR - Cas - 9 gene - editing technology can be used to target the root genetic deficiency at the heart of the disease.

The Bill and Melinda Gates Foundation sees so much promise in gene drive technology that it plans to double spending on its Target Malaria initiative, which aims to create systems for driving genes in two species of malaria mosquitoes, to $ 70 million.

«We spent half a dozen years trying to target the beta globin gene using the old technology,» he noted, adding that within one week of trying CRISPR, they had an editing tool that worked much better.

However, this technology requires an exact match with any targeted gene.

Researchers from KTH Royal Institute of Technology's Science for Life Laboratory (SciLifeLab) research center and Gothenburg University employed the biological networks generated for 46 major human tissues in order to identify the liver - specific gene targets.

The study adds to evidence that gene editing may need to be adapted to each patient's genome, to ensure there aren't variants in DNA sequence in or near the gene being targeted that would throw off the technology.

«So, with this knowledge, the dream is that we could eventually use gene editing technology to edit the microRNA target sites in the host plants, preventing the microRNAs from binding and silencing these genes.

He has worked in the biotech industry as a research scientist for over 11 years with a focus on emerging technologies including gene targeting in mice, molecular analysis of transgenes using GFP variants at the single cell level, and developing flow cytometry reagent kits to speed up assay development time for researchers.

Choudhury used high - throughput sequencing technology to find the targets of DAZAP1 and decipher whether DAZAP1 would bind to the exons and introns of genes.

Derived mostly from human embryonic kidney 293T (HEK293T) and HeLa cell lines, EdiGene Knockout (KO) Cell Lysates have been optimized through the use of genome editing technology and validated at the genomic level through PCR and Sanger - sequencing techniques to ensure the accuracy and knockout of the target gene.

The convergence of several factors explains the trend: cheaper genetic sequencing technologies, the discovery of new oncogenes (genes that can cause a normal cell to become cancerous), a new generation of computers and bioinformatics that can analyze vast amounts of data, and a multibillion - dollar effort by researchers inside and outside the pharma industry to develop targeted drugs and companion diagnostics for cancer.

The marriage of Professors Capecchi and Smithies» homologous recombination technique with Sir Martin's stem cell discoveries has created the highly versatile new technology of gene targeting.

Their research has created the technology known as gene targeting, now used in virtually all areas of biomedicine — from basic research to the development of new therapies.

However, like most gene transfer approaches a major concern with ZFN technology is the potential for oncogenesis due to off - target effects.

First author Dr Reza Haqshenas said the researchers then used gene silencing technology to determine whether the genes» cell factors identified using the antibody microarray were indeed important for HCV replication and therefore potential targets for anti-HCV compounds.

Caribou's market - leading CRISPR - Cas9 gene editing technology can accurately target and cut DNA to produce precise and controllable changes to the genome, which can be applied by JAX to create mouse models that better recapitulate human diseases enabling researchers to find better treatments faster.

The advancement of the Cas9 - based platform for screening and validation will help further the development of new therapeutic products, and Caribou's CRISPR - Cas9 technology can utilize guide RNAs specific for unique sequences and target a gene at numerous sites and therefore provide enhanced specificity.

The CRISPR - Cas technology can be used to screen for druggable targets and to develop gene and cell therapies for unmet medical needs.

Drug discovery for genetic diseases: Screening technologies are applied to identify chemical compounds able to inhibit REST function, a major target gene in Huntington's disease, and will serve as a paradigm for high - throughput screening approaches applied to neurological disorders.

This technology helps researchers connect mutations in the so - called genomic «dark matter» with the genes they affect, potentially revealing new therapeutic targets for genetic disorders.

Intellia will utilize Caribou's proprietary CRISPR - Cas9 gene editing and repair technology platform in the development of new therapies targeting a variety of genetic - based diseases.

Karl Campbell from Island Conservation reported on his organization's investigation into using gene - drive technology as potentially the most targeted, effective, and economic technique for eliminating invasive mice and rats.

use CRISPR - Cas technology to carry out genome - wide screens of gene - gene, gene - drug and cancer - microenvironment interactions in cells and mice in order to explore fundamental biology and to identify drug targets and drug resistance / sensitisation mechanisms.

The CRISPR / Cas technology applied to mouse genetic engineering could quickly advance scientific understanding of disease mechanisms by allowing researchers to ask complex questions and find answers much faster than with traditional gene targeting approaches.

Developed in collaboration with the Laboratory Medicine, Information Technology and Health Science Research departments of Mayo Clinic Geneticist Assistant NGS Interpretative Workbench, is a web - based tool for the control, visualization, interpretation and historical knowledge base of next generation sequencing data targeted at specific genes for the purpose of identifying potentially pathogenic variants associated with specific conditions such as hereditary colon cancer.

Scientific meeting «Gene targeting, genome editing & transgenesis: research application» We are organizing joint meeting with our colleagues from Masaryk University in Brno dedicated to current progress in transgenic technologies in research application, animal models of diseases and Wnt signalling.

«Simultaneous mutation detection, copy number measurement, and digital gene expression profiling of high - grade serous ovarian cancer FFPE samples using Hyb & SeqTM targeted sequencing technology»

Same basic technology, but targeting a different gene.

These knockout cell lines allow researchers to quickly validate their gene or target of interest, without having to invest time and resource in developing in - house CRISPR technology.

This technology can be applied to gene expression, SNPs (single nucleotide polymorphisms) and proteomics data to improve diagnostic and drug target identification and prioritization, predictive toxicology and drug screening.

This includes targeting gene - editing technologies like CRISPR, which has recently opened up new doors for precise genome manipulation and gene therapy.

«With this technology, you can test the function of these candidate genes and measure what percentage of cells are generating into our target arterial cells,» says Zhang.

He completed his postdoctoral studies in gene targeting and DNA recombination at Massachusetts Institute of Technology (MIT).

Participants will learn design of CRISPR targets using bioinformatics tools, generation of gene knockouts / knock - ins, and target validation using the most current technologies.

Title: Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: R. Venkatramanan et al, Covance Poster # / Location: 3418 / Section 16, Board 3 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7089 A comparison of PlexSet technology with various qPCR technologies on 96 colorectal FFPE samples.

To repair the problem, the research team «broke» the mutated version of the MYPBC3 gene inside human embryos, using technology that allows scientists to snip a specific target sequence on a mutant gene.